COVID-19 Pandemic: Are We Back to Normal?

Competing Interests: Disclosure: A.H. would like to disclose that he received remuneration from Adom, Qlaris, and Luseed for serving as a consultant, and he serves on the board of Adom and Phileas Pharma. A.H. also holds an ownership interest in AdOM, Luseed, Oxymap, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine’s policy on outside activities. J.C.T. is a paid consultant for Eyenovia and ReNetX Bio. The contribution of the author A.C.V.V. was supported by Fondazione Roma and by the Italian Ministry of Health. The remaining authors declare no conflict of interest.